Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
This research study is studying a combination of drugs as a possible treatment for rare genitourinary malignancies.
-The names of the study drugs involved in this study are:
A phase II study of nivolumab combined with ipilimumab for patients with advanced rare genitourinary tumors
- ClinicalTrials.gov Identifier: NCT03333616
- Protocol Number: 17-423
- Principal Investigator: Glenn Bubley
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required